{"id":{"repo_id":"mtu","oai_identifier":"oai:digitalcommons.mtu.edu:etdr-2737"},"canonical_url":"https://search.ndltd.org/etd/mtu/oai:digitalcommons.mtu.edu:etdr-2737","repository":{"repo_id":"mtu","name":"Michigan Technological University","base_url":"https://digitalcommons.mtu.edu/do/oai/"},"display":{"title":"Dissecting the Role of Selenoprotein P and Thioredoxin Reductase in Pancreatic Cancer Metabolism","abstract":"Pancreatic ductal adenocarcinoma (PDAC), the fourth leading cause of US cancer-related deaths, has a stark 5-year survival rate of 9%, emphasizing an urgent need for effective therapies. A well-established characteristic of cancer, metabolic dysregulation, presents an opportunity for developing therapies that target specific metabolic susceptibilities inherent in cancer cells. Our recent studies have discovered a susceptibility in PDAC; deprivation of cystine or blocking its uptake by erastin (a cystine transport inhibitor) triggers significant lipid peroxidation, thereby inducing ferroptosis specifically in the mesenchymal subtype of PDAC, but not in the epithelial subtype. This study aims to elucidate the roles of Selenoprotein P (Sepp1) and Thioredoxin Reductase (TrxR) in epithelial PDAC. Using RNAi and CRISPR-CAS9 methodologies, we found that the activity of TrxR2 is responsible for drug resistance in epithelial PDAC, while Sepp1 and TrxR1 are unnecessary. These findings could significantly contribute to novel therapeutic developments.","abstract_html":"Pancreatic ductal adenocarcinoma (PDAC), the fourth leading cause of US cancer-related deaths, has a stark 5-year survival rate of 9%, emphasizing an urgent need for effective therapies. A well-established characteristic of cancer, metabolic dysregulation, presents an opportunity for developing therapies that target specific metabolic susceptibilities inherent in cancer cells. Our recent studies have discovered a susceptibility in PDAC; deprivation of cystine or blocking its uptake by erastin (a cystine transport inhibitor) triggers significant lipid peroxidation, thereby inducing ferroptosis specifically in the mesenchymal subtype of PDAC, but not in the epithelial subtype. This study aims to elucidate the roles of Selenoprotein P (Sepp1) and Thioredoxin Reductase (TrxR) in epithelial PDAC. Using RNAi and CRISPR-CAS9 methodologies, we found that the activity of TrxR2 is responsible for drug resistance in epithelial PDAC, while Sepp1 and TrxR1 are unnecessary. These findings could significantly contribute to novel therapeutic developments.","abstract_has_math":false,"creators":["Abbas, Alyssa A."],"institution":null,"degree_name":"Master of Science in Biological Sciences (MS)","degree_level":"Open Access Master's Report","degree_discipline":"Department of Biological Sciences","degree_department":null,"school":null,"contributors":["Xiaohu Tang"],"advisors":[],"committee_chairs":[],"committee_members":["Paul Goetsch","Stephen Techtmann"],"year":null,"date_issued":"","date_published":null,"updated_at":"2026-11-19T08:18:53Z","subjects":["Pancreatic cancer","selenoproteins","selenoprotein p","thioredoxin reductase","Biology","Cancer Biology","Cell Biology"],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[{"key":"dc:identifier","label":"Identifier","values":["https://digitalcommons.mtu.edu/etdr/1618"],"render_values":[{"text":"https://digitalcommons.mtu.edu/etdr/1618","href":"https://digitalcommons.mtu.edu/etdr/1618","code":true}]}],"person_identifier_entries":[]},"links":{"outbound_url":"https://doi.org/10.37099/mtu.dc.etdr/1618","outbound_label":"DOI","outbound_source":"dc:identifier","record_url":"https://doi.org/10.37099/mtu.dc.etdr/1618","record_label":"Repository record","record_kind":"doi","record_source":"dc:identifier","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://digitalcommons.mtu.edu/do/oai/?verb=GetRecord&metadataPrefix=oai_etdms&identifier=oai%3Adigitalcommons.mtu.edu%3Aetdr-2737","prefix":"oai_etdms"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Xiaohu Tang"]},{"key":"dc:contributor.committeemember","label":"Committee Member","values":["Paul Goetsch","Stephen Techtmann"]},{"key":"dc:creator","label":"Author","values":["Abbas, Alyssa A."]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.created","label":"Dc Date Created","values":["2023-01-01T08:00:00Z"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Department of Biological Sciences"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Open Access Master's Report"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Master of Science in Biological Sciences (MS)"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Pancreatic cancer","selenoproteins","selenoprotein p","thioredoxin reductase","Biology","Cancer Biology","Cell Biology"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["10.37099/mtu.dc.etdr/1618","https://digitalcommons.mtu.edu/etdr/1618"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Pancreatic ductal adenocarcinoma (PDAC), the fourth leading cause of US cancer-related deaths, has a stark 5-year survival rate of 9%, emphasizing an urgent need for effective therapies. A well-established characteristic of cancer, metabolic dysregulation, presents an opportunity for developing therapies that target specific metabolic susceptibilities inherent in cancer cells. Our recent studies have discovered a susceptibility in PDAC; deprivation of cystine or blocking its uptake by erastin (a cystine transport inhibitor) triggers significant lipid peroxidation, thereby inducing ferroptosis specifically in the mesenchymal subtype of PDAC, but not in the epithelial subtype. This study aims to elucidate the roles of Selenoprotein P (Sepp1) and Thioredoxin Reductase (TrxR) in epithelial PDAC. Using RNAi and CRISPR-CAS9 methodologies, we found that the activity of TrxR2 is responsible for drug resistance in epithelial PDAC, while Sepp1 and TrxR1 are unnecessary. These findings could significantly contribute to novel therapeutic developments."]},{"key":"dc:title","label":"Title","values":["Dissecting the Role of Selenoprotein P and Thioredoxin Reductase in Pancreatic Cancer Metabolism"]}]}],"canonical_facts":{"dc:contributor":["Xiaohu Tang"],"dc:contributor.committeemember":["Paul Goetsch","Stephen Techtmann"],"dc:creator":["Abbas, Alyssa A."],"dc:date.created":["2023-01-01T08:00:00Z"],"dc:description.abstract":["Pancreatic ductal adenocarcinoma (PDAC), the fourth leading cause of US cancer-related deaths, has a stark 5-year survival rate of 9%, emphasizing an urgent need for effective therapies. A well-established characteristic of cancer, metabolic dysregulation, presents an opportunity for developing therapies that target specific metabolic susceptibilities inherent in cancer cells. Our recent studies have discovered a susceptibility in PDAC; deprivation of cystine or blocking its uptake by erastin (a cystine transport inhibitor) triggers significant lipid peroxidation, thereby inducing ferroptosis specifically in the mesenchymal subtype of PDAC, but not in the epithelial subtype. This study aims to elucidate the roles of Selenoprotein P (Sepp1) and Thioredoxin Reductase (TrxR) in epithelial PDAC. Using RNAi and CRISPR-CAS9 methodologies, we found that the activity of TrxR2 is responsible for drug resistance in epithelial PDAC, while Sepp1 and TrxR1 are unnecessary. These findings could significantly contribute to novel therapeutic developments."],"dc:identifier":["10.37099/mtu.dc.etdr/1618","https://digitalcommons.mtu.edu/etdr/1618"],"dc:subject":["Pancreatic cancer","selenoproteins","selenoprotein p","thioredoxin reductase","Biology","Cancer Biology","Cell Biology"],"dc:title":["Dissecting the Role of Selenoprotein P and Thioredoxin Reductase in Pancreatic Cancer Metabolism"],"thesis:degree_discipline":["Department of Biological Sciences"],"thesis:degree_level":["Open Access Master's Report"],"thesis:degree_name":["Master of Science in Biological Sciences (MS)"]},"updated_at":"2026-11-19T08:18:53Z"}